Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 10
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
E7389-A001-201
NCT00097721
2.
Phase II Study Of E7389, Halichondrin B Analog, In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed During Or After Platinum-Based Doublet Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
E7389-A001-202
NCT00100932
3.
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
E7389-G000-211
NCT00246090
4.
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
E7389-G000-204
NCT00278993
Last Modified:
12/19/2007
 
First Published:
6/9/2006
5.
Phase II Study of E7389 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
SWOG-S0618
S0618, NCT00337129
Last Modified:
2/14/2008
 
First Published:
9/23/2006
6.
Phase II Study of E7389 as Second-Line Therapy in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Temporarily closed
18 and over
NCI
PMH-PHL-049
7448, NCI-7448, NCT00383760
Last Modified:
1/13/2009
 
First Published:
11/13/2006
7.
Phase II Study of E7389 in Patients With Recurrent or Progressive Stage IIIB or IV Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
CCC-PHII-74
7437, NCT00400829
Last Modified:
11/20/2007
 
First Published:
10/1/2002
8.
Phase I Study of E7389 in Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
CCC-PHI-39
CHNMC-PHI-39, NCI-5730, NCT00047034, 5730
9.
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
over 18
Pharmaceutical / Industry
E7389-A001-102
NCT00069277
10.
Phase I Clinical Study of E7389
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
20 to 74
Pharmaceutical / Industry
E7389-J081-105
NCT00326950
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute